Medical treatment in Cushing's syndrome: Dopamine agonists and cabergoline

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 116-119

  Petrossians, Patrick ^a   Thonnard, Anne Sophie ^a   Beckers, Albert ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adenoma; Adrenocorticotropic hormone; Cabergoline; Cortisol; Cushing's disease; Dopamine agonists; Ectopic

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; KETOCONAZOLE;

ACTH SECRETING ADENOMA; ADRENAL CORTEX ADENOMA; ADRENALECTOMY; CLINICAL FEATURE; CONFERENCE PAPER; CUSHING DISEASE; CUSHING SYNDROME; DRUG HALF LIFE; DRUG INDICATION; ECTOPIC CORTICOTROPIN PRODUCTION; HUMAN; HYPOPHYSECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

CUSHING SYNDROME; DOPAMINE AGONISTS; ERGOLINES; HUMANS;

EID: 77956510120     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317716     Document Type: Conference Paper

References (23)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing's syndrome. Lancet 2006; 367:1605-1617.
2. De Bruin C, Feelders RA, Lamberts SW, Hofland LJ: Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Rev Endocr Metab Disord 2009; 10:91-102.
3. Ferone D, Gatto F, Arvigo M, et al: The clinical-molecular interface of somatostatin, do-pamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009; 42: 361-370.
4. Pivonello R, Ferone D, Lombardi G, et al: Novel insights in dopamine receptor physi-olog y. Eur J Endocrinol 2007; 156:S13-S21.
5. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-22 5.
6. Pivonello R, Ferone D, De Herder WW, et al: Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin En-docrinol Metab 2004; 89:2452-2462. (Pubitemid 38619889)
7. Farrell WE, Clark AJ, Stewart MF, Crosby SR, White A: Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH pre-c u rs or secret ion in sm a l l c el l lu ng c a nc er cel l lines. J Clin Invest 1992; 90:705-710.
8. Pivonello R, Ferone D, De Herder WW, et al: Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endo-crinol Metab 2007; 92:65-69.
9. Pivonello R, Ferone D, De Herder WW, et al: Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 2004; 89: 4493-4502. (Pubitemid 39244461)
10. Miller JW, Crapo L: The medical treatment of Cushing's syndrome. Endocr Rev 1993; 14: 443-458.
11. Petrossians P, Ronci N, Valdés Socin H, et al: ACTH silent adenoma shrinking under cab-ergoline. Eur J Endocrinol 2001; 14 4: 51-5 7.
12. Miyoshi T, Otsuka F, Takeda M, et al: Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotro-pin-secreting macroadenoma. J Endocrinol Invest 2004; 27:1055-1059.
13. Pivonello R, De Martino MC, Cappabianca P, et al: The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 20 09; 94: 223-230.
14. Isidori AM, Kaltsas GA, Pozza C, et al: The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006; 91:371-377.
15. Daly AF, Rixhon M, Adam C, et al: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775.
16. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR: Publication bias in clinical research. Lancet 1991; 337:867-872.
17. Callaham ML, Wears RL, Weber EJ, Barton C, Young G: Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. JAMA 1998; 280:254-257.
18. Scha De R, Andersoh n F, Su i s sa S, H averk a mp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
19. Zanettini R, Antonini A, Gatto G, et al: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46.
20. Lancellotti P, Livadariu E, Markov M, et al: Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008; 159:1-5.
21. Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P: Use of cabergoline in persisting Cushing's disease. Ann Endocri-nol 2006; 67: 353-356.
22. Godbout ABH, Babin S, Sabourin A, Lacroix A: Cabergoline in the longterm treatment of Cushing's disease: preliminary safety and efficacy results of a phase II study. Endocrine Society's 89th Annual Meeting, 2007.
23. Vilar L, Naves LA, Azevedo MF, et al: Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitar y 2010; 13: 123-129.